Sun Pharma's Mohali plant in Punjab receives OAI status from USFDA

Sun Pharmaceutical Industries said that their Mohali plant in Punjab received an official action indicated (OAI) classification from the US Food and Drug Administration (USFDA). This can impact approvals pending for products, but does not impact the current business from the facility. 

The plant was inspected in August and had received a form 483 with six observations earlier. The typical process is that the firm concerned responds to the queries raised by the FDA  and a resolution is based on whether the FDA is satisfied by the corrective actions taken by the company. Sun Pharma has now received communication from